Breakdown | |||||
TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
35.32B | 36.80B | 35.46B | 33.48B | 27.77B | 20.31B | Gross Profit |
9.01B | 9.54B | 9.35B | 10.50B | 7.88B | 4.94B | EBIT |
5.45B | 6.10B | 6.42B | 7.57B | 5.32B | 2.83B | EBITDA |
5.55B | 6.37B | 6.19B | 7.65B | 5.40B | 2.91B | Net Income Common Stockholders |
4.29B | 4.76B | 4.75B | 5.86B | 4.18B | 2.37B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
3.09B | 4.54B | 3.87B | 2.54B | 3.21B | 3.02B | Total Assets |
34.40B | 36.10B | 32.58B | 30.35B | 24.02B | 18.91B | Total Debt |
5.99B | 5.97B | 5.09B | 6.07B | 5.41B | 4.28B | Net Debt |
2.89B | 1.45B | 1.22B | 3.53B | 2.20B | 1.26B | Total Liabilities |
10.10B | 10.28B | 9.44B | 10.57B | 8.80B | 6.79B | Stockholders Equity |
23.82B | 25.31B | 22.70B | 19.40B | 14.89B | 11.84B |
Cash Flow | Free Cash Flow | ||||
2.74B | 2.02B | 4.16B | 413.60M | 267.00M | 1.13B | Operating Cash Flow |
2.87B | 2.19B | 4.30B | 561.80M | 534.40M | 1.42B | Investing Cash Flow |
-219.10M | -190.60M | -310.20M | -414.90M | -252.20M | -166.10M | Financing Cash Flow |
-3.23B | -1.36B | -2.67B | -811.20M | -85.10M | 270.60M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $20.93B | 7.37 | 25.52% | 0.80% | 8.86% | 13.60% | |
79 Outperform | $10.67B | 7.38 | 20.38% | 0.88% | 5.86% | 12.20% | |
79 Outperform | $6.02B | 6.98 | 15.97% | ― | 12.19% | 23.15% | |
76 Outperform | $21.38B | 15.05 | 38.25% | ― | 8.81% | 1.79% | |
75 Outperform | $38.63B | 9.51 | 17.83% | 1.11% | -4.71% | -10.19% | |
71 Outperform | $29.20B | 8.15 | 14.97% | 1.79% | 2.03% | -3.80% | |
61 Neutral | $6.97B | 11.38 | 2.88% | 3.90% | 2.64% | -22.07% |
DR Horton has entered into a material definitive agreement, which has implications for its financial obligations. The details of this agreement are expected to impact the company’s operations and may influence its market positioning, although specific implications for stakeholders are not detailed.
Spark’s Take on DHI Stock
According to Spark, TipRanks’ AI Analyst, DHI is a Outperform.
DR Horton’s strong financial performance, efficient cash flow management, and undervaluation are significant strengths. However, potential challenges in maintaining growth momentum and recent technical indicators suggest caution. The earnings call points to resilience, but decreased sales and increased expenses are areas to monitor.
To see Spark’s full report on DHI stock, click here.